128 related articles for article (PubMed ID: 37916667)
1.
Eckernäs E; Macan-Schönleben A; Andresen-Bergström M; Birgersson S; Hoffmann KJ; Ashton M
Xenobiotica; 2023 Dec; 53(8-9):515-522. PubMed ID: 37916667
[No Abstract] [Full Text] [Related]
2. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of N,N-dimethyltryptamine in Humans.
Good M; Joel Z; Benway T; Routledge C; Timmermann C; Erritzoe D; Weaver R; Allen G; Hughes C; Topping H; Bowman A; James E
Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):311-327. PubMed ID: 37086340
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
5. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.
Erickson DA; Hollfelder S; Tenge J; Gohdes M; Burkhardt JJ; Krieter PA
Drug Metab Dispos; 2007 Dec; 35(12):2232-41. PubMed ID: 17881661
[TBL] [Abstract][Full Text] [Related]
9. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine.
Yu AM; Granvil CP; Haining RL; Krausz KW; Corchero J; Küpfer A; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2003 Feb; 304(2):539-46. PubMed ID: 12538805
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
11. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
12. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
13. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
Dalmadi B; Leibinger J; Szeberényi S; Borbás T; Farkas S; Szombathelyi Z; Tihanyi K
Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
[TBL] [Abstract][Full Text] [Related]
14. Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A.
Noble C; Holm NB; Mardal M; Linnet K
Toxicol Lett; 2018 Oct; 295():397-407. PubMed ID: 30036687
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of sumatriptan revisited.
Pöstges T; Lehr M
Pharmacol Res Perspect; 2023 Feb; 11(1):e01051. PubMed ID: 36655303
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.
Nakamura K; Yokoi T; Inoue K; Shimada N; Ohashi N; Kume T; Kamataki T
Pharmacogenetics; 1996 Oct; 6(5):449-57. PubMed ID: 8946477
[TBL] [Abstract][Full Text] [Related]
17. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
18. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes.
Tang L; Ye L; Lv C; Zheng Z; Gong Y; Liu Z
Toxicol Lett; 2011 Apr; 202(1):47-54. PubMed ID: 21277363
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
Sanwald P; David M; Dow J
Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study.
Riba J; McIlhenny EH; Bouso JC; Barker SA
Drug Test Anal; 2015 May; 7(5):401-6. PubMed ID: 25069786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
